Anti-ENA6 Plus DFS70Ab Profile

Serum

3 mL

1.5 mL (Note: This volume does not allow for repeat testing.)

Red-top tube or gel-barrier tube

Anti-ENA6 Plus DFS70 is designed to facilitate the proper triage of patients with positive Anti-Nuclear Antibodies (ANA) by identifying those most likely to benefit from a rheumatology specialist. It detects the novel Anti-DFS70 along with 6 other clinically useful autoantibodies to ENA, which may help identify systemic lupus erythematous (SLE), mixed connective tissue disease (MCTD), Sjogren's, systemic sclerosis, and idiopathic inflammatory myopathy (IIM). Positive Anti-DFS70 antibodies in isolation may help identify individuals who do not have an AARD (ANA-associated rheumatic disease), especially in the absence of significant clinical findings.

Anti-DFS70 Abs confer a likelihood ratio for the absence of systemic autoimmune rheumatic disease of 10.9 and are detectable in 2% to 22% of healthy individuals and in less than 1% of patients with AARD.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

See individual test components.